Literature DB >> 24377038

Modeling the time dependent distribution of a new (153)Sm complex for targeted radiotherapy purpose.

Dariush Sardari1, Amir Hakimi1.   

Abstract

BACKGROUND: For radioimmunotherapy purposes, a chemical complex with high absorption in cancer tumor is required. New chemicals are to be examined for their concentration in tumor and healthy organs. These are labeled with β-emitting radioisotopes to irradiate the tumor while deposited inside it. AIM: To study the capability of recently developed chemical complex in targeting cancer tumor and investigate the distribution of (153)Sm-TPTTC in rat organs as function of time.
MATERIALS AND METHODS: The chemical complex - [Tris(1,10-phenanthroline)Samarium(III)] trithiocyanate was prepared and labeled with (153)Sm radioisotope. The labeled complex was injected to a population of tumor bearing mice. In 2, 4, 24, 48, 96 h after injection the animals were sacrificed and the concentration of Samarium complex was measured in various organs such as blood, heart, intestine, colon, liver, spleen, kidney, sternum and bone.
RESULTS: The concentration of the radiopharmaceutical in various organs was measured at different times. The temporal behavior of biodistribution of (153)Sm-TPTTC was modeled and drawn as function of time.
CONCLUSION: It is shown that (153)Sm-TPTTC is concentrated in tumor tissue and liver much more than in other organs. The variation of pharmaceutical concentration in all organs is described with summation of eight exponential terms and it approximates our experimental data with precision better than 2%.

Entities:  

Keywords:  Biodistribution; Cancer targeted radiotherapy; Compartmental analysis; Mathematical modeling

Year:  2012        PMID: 24377038      PMCID: PMC3863299          DOI: 10.1016/j.rpor.2012.07.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  7 in total

1.  S values for radionuclides localized within the skeleton.

Authors:  L G Bouchet; W E Bolch; R W Howell; D V Rao
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

Review 2.  Tumor transport physiology: implications for imaging and imaging-guided therapy.

Authors:  B S Kuszyk; F M Corl; F N Franano; D A Bluemke; L V Hofmann; B J Fortman; E K Fishman
Journal:  AJR Am J Roentgenol       Date:  2001-10       Impact factor: 3.959

Review 3.  Early development of therapeutic biologics--pharmacokinetics.

Authors:  A Baumann
Journal:  Curr Drug Metab       Date:  2006-01       Impact factor: 3.731

4.  Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease.

Authors:  Mónica Coronado; Andrés Redondo; Juan Coya; Enrique Espinosa; Rosa M Couto; Pilar Zamora; Maria Dolores Marin; Beatriz Castelo; Maria Eugenia Lillo; Laura Frutos; Manuel González Barón; Luis M Martín Curto
Journal:  Clin Nucl Med       Date:  2006-10       Impact factor: 7.794

5.  Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy.

Authors:  H Zhu; R J Melder; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

6.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model.

Authors:  L T Baxter; H Zhu; D G Mackensen; W F Butler; R K Jain
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

7.  Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

Authors:  W F Goeckeler; B Edwards; W A Volkert; R A Holmes; J Simon; D Wilson
Journal:  J Nucl Med       Date:  1987-04       Impact factor: 10.057

  7 in total
  1 in total

1.  Modeling the time dependent biodistribution of Samarium-153 ethylenediamine tetramethylene phosphonate using compartmental analysis.

Authors:  Parandoush Abbasian; Monika Foroghy; Amir Reza Jalilian; Amir Hakimi; Simindokht Shirvani-Arani
Journal:  Rep Pract Oncol Radiother       Date:  2013-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.